BioXcel Appoints Dr. Peter Mueller as Chairman of Scientific Advisory Board
SAB to Guide Advancement of Multiple Therapeutic Programs
BRANFORD, Conn., Oct. 12, 2016 (GLOBE NEWSWIRE) -- BioXcel, a privately held biopharmaceutical company based in Connecticut, today announced the appointment of Dr. Peter Mueller, Ph.D. as Chairman of its Scientific Advisory Board (“SAB”), which will serve as a strategic resource to the Company as it advances its clinical pipeline of immuno-oncology and neuroscience candidates.
"We are thrilled to have Dr. Mueller join BioXcel as the Chairman of our Scientific Advisory Board. He has tremendous expertise in drug discovery and development, which we believe will be valuable in shaping the strategic direction of the Company. We look forward to gaining counsel from Dr. Mueller on the assessment of various scientific and clinical opportunities as well as ongoing development of our pipeline programs. We plan to further expand our SAB to include renowned key opinion leaders in oncology, neuroscience, and technology who will play a key role in BioXcel’s scientific and clinical development initiatives," said Dr. Vimal D. Mehta, CEO and Chairman of BioXcel.
Currently, Dr. Peter Mueller is the President of R&D and Chief Scientific Officer at Axcella Health. Prior to joining Axcella, Dr. Mueller served as the Executive Vice President of Global Research and Development & Chief Scientific Officer at Vertex Pharmaceuticals where he provided strategic oversight for Vertex’s worldwide drug discovery and development programs. Under his leadership, the company secured approval for and launched two breakthrough drugs, INCIVEK® (HepC) in 2011, and KALYDECO® (CF) in 2012. Additionally, Vertex submitted both an NDA and MAA for ORKAMBI® (CF). Prior to his time at Vertex, Dr. Mueller served as Senior Vice President, Research and Development, for Boehringer Ingelheim Pharmaceuticals, Inc., where he played a key role in the development of Spiriva®, Combivent®, and Atrovent®. He is a member of various scientific and political societies, including the Gesellschaft Deutscher Chemiker (GDCh) and Verband Chemische Industrie (Germany), Royal Society of Chemistry (U.K.), IRI, RNA-Society, ASAP, AAAS (U.S.A.) and currently serves on several Boards and Scientific Advisory Board in companies and organizations including US-India Chamber of Commerce Biotech, Pharma & Medical Devices Council, University Iowa (CBB), Keystone Symposia, Inhibikase Therapeutics, Inc., and Kaleido Biosciences, Inc.
Dr. Mueller received both an undergraduate degree and a Ph.D. in chemistry at the Albert Einstein University of Ulm, Germany, where he also holds a Professorship in Theoretical Organic Chemistry. He completed fellowships in Quantum Pharmacology at Oxford University and in Biophysics at Rochester University.
“I am very pleased to chair the Scientific Advisory Board and work with the BioXcel team to advance the Company’s current and future therapeutic programs. BioXcel is taking a unique and exciting approach to drug discovery and development that should bring new therapies to market in a more efficient manner, targeting areas of high unmet medical need. I am excited to support the team as they work to bring these innovative therapies to the market," stated Dr. Peter Mueller, Ph.D., Chairman of BioXcel’s Scientific Advisory Board.
BioXcel is a biopharmaceutical company pioneering the integration of big data analytics and machine learning-based artificial intelligence with drug development expertise to advance the next wave of medicines, impacting the probability of success of drugs. Our focus is to develop innovative medicines that address immuno-oncology and neuroscience diseases with high unmet medical need. Committed to innovation, product excellence and partner success, BioXcel's global collaborations span the biopharmaceutical ecosystem. We are headquartered in Branford, CT, USA with operations in Asia.
Contact Information: Anita Ganjoo, Ph.D. Corporate Communications 203 957 2487Source: BioXcel Corporation
Released October 12, 2016